PubRank

Jan Ravkilde

Author PubWeight™ 95.37‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Universal definition of myocardial infarction. Circulation 2007 11.69
2 Third universal definition of myocardial infarction. J Am Coll Cardiol 2012 8.59
3 Third universal definition of myocardial infarction. Circulation 2012 8.47
4 Third universal definition of myocardial infarction. Eur Heart J 2012 7.98
5 Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. Lancet 2015 3.87
6 Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005 2.43
7 Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial. Lancet 2013 2.39
8 Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. JAMA 2008 2.39
9 Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet 2010 2.38
10 National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation 2007 2.37
11 Randomized study on simple versus complex stenting of coronary artery bifurcation lesions: the Nordic bifurcation study. Circulation 2006 2.09
12 National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin Chem 2007 1.82
13 Quality specifications for B-type natriuretic peptide assays. Clin Chem 2005 1.81
14 Comparison of outcomes in patients with versus without diabetes mellitus after revascularization with everolimus- and sirolimus-eluting stents (from the SORT OUT IV trial). Am J Cardiol 2012 1.59
15 Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin Chem 2003 1.51
16 Moderate overweight is beneficial and severe obesity detrimental for patients with documented atherosclerotic heart disease. Heart 2013 1.47
17 Late lumen loss and intima hyperplasia after sirolimus-eluting and zotarolimus-eluting stent implantation in diabetic patients: the diabetes and drug-eluting stent (DiabeDES III) angiography and intravascular ultrasound trial. EuroIntervention 2011 1.43
18 Sex- and age-related differences in clinical outcome after primary percutaneous coronary intervention. EuroIntervention 2012 1.42
19 National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Circulation 2007 1.39
20 National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biochemical markers of acute coronary syndromes. Clin Chem 2007 1.19
21 Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV). Circulation 2012 1.17
22 Long-term results after simple versus complex stenting of coronary artery bifurcation lesions: Nordic Bifurcation Study 5-year follow-up results. J Am Coll Cardiol 2013 1.14
23 Randomized comparison of final kissing balloon dilatation versus no final kissing balloon dilatation in patients with coronary bifurcation lesions treated with main vessel stenting: the Nordic-Baltic Bifurcation Study III. Circulation 2010 1.13
24 Randomized comparison of distal protection versus conventional treatment in primary percutaneous coronary intervention: the drug elution and distal protection in ST-elevation myocardial infarction (DEDICATION) trial. J Am Coll Cardiol 2008 1.08
25 National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. Clin Chem 2007 1.08
26 Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 3-year follow-up of the randomized DEDICATION (Drug Elution and Distal Protection in Acute Myocardial Infarction) Trial. J Am Coll Cardiol 2010 1.04
27 Drug-eluting versus bare metal stents in patients with st-segment-elevation myocardial infarction: eight-month follow-up in the Drug Elution and Distal Protection in Acute Myocardial Infarction (DEDICATION) trial. Circulation 2008 1.02
28 Randomized comparison of coronary bifurcation stenting with the crush versus the culotte technique using sirolimus eluting stents: the Nordic stent technique study. Circ Cardiovasc Interv 2009 0.98
29 Dimensions of socioeconomic status and clinical outcome after primary percutaneous coronary intervention. Circ Cardiovasc Interv 2012 0.96
30 Outcome of sirolimus-eluting versus zotarolimus-eluting coronary stent implantation in patients with and without diabetes mellitus (a SORT OUT III Substudy). Am J Cardiol 2011 0.95
31 A pilot survey of the use and implementation of cardiac markers in acute coronary syndrome and heart failure across Europe. The CARdiac MArker Guideline Uptake in Europe (CARMAGUE) study. Clin Chem Lab Med 2009 0.91
32 Acute coronary angiography in patients resuscitated from out-of-hospital cardiac arrest--a systematic review and meta-analysis. Resuscitation 2012 0.90
33 Deferred stent implantation in patients with ST-segment elevation myocardial infarction: a pilot study. EuroIntervention 2013 0.89
34 Evidence-based laboratory medicine: how well do laboratories follow recommendations and guidelines? The Cardiac Marker Guideline Uptake in Europe (CARMAGUE) study. Clin Chem 2011 0.88
35 Diagnostic value of ischemia-modified albumin in patients with suspected acute coronary syndrome. Am J Emerg Med 2010 0.87
36 2-year patient-related versus stent-related outcomes: the SORT OUT IV (Scandinavian Organization for Randomized Trials With Clinical Outcome IV) Trial. J Am Coll Cardiol 2012 0.86
37 Event detection using population-based health care databases in randomized clinical trials: a novel research tool in interventional cardiology. Clin Epidemiol 2013 0.86
38 Safety in simple versus complex stenting of coronary artery bifurcation lesions. The nordic bifurcation study 14-month follow-up results. EuroIntervention 2008 0.84
39 Primary percutaneous coronary intervention as a national reperfusion strategy in patients with ST-segment elevation myocardial infarction. Circ Cardiovasc Interv 2011 0.84
40 Influence of diabetes mellitus on clinical outcomes following primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2011 0.83
41 Comparison of outcomes of patients ≥ 80 years of age having percutaneous coronary intervention according to presentation (stable vs unstable angina pectoris/non-ST-segment elevation myocardial infarction vs ST-segment elevation myocardial infarction). Am J Cardiol 2011 0.82
42 Clinical performance of a new point-of-care cardiac troponin I assay compared to three laboratory troponin assays. Clin Chim Acta 2010 0.82
43 Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 5 years follow-up from the randomized DEDICATION trial (Drug Elution and Distal Protection in Acute Myocardial Infarction). JACC Cardiovasc Interv 2013 0.81
44 Kinetics of ischaemia modified albumin during ongoing severe myocardial ischaemia. Clin Chim Acta 2009 0.81
45 Methylated arginines in stable and acute patients with coronary artery disease before and after percutaneous revascularization. Int J Cardiol 2007 0.81
46 Zotarolimus-eluting vs. sirolimus-eluting coronary stents in patients with and without acute coronary syndromes: a SORT OUT III substudy. Eur J Clin Invest 2012 0.81
47 3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents. JACC Cardiovasc Interv 2012 0.81
48 Effect of remote ischaemic conditioning on clinical outcomes in patients presenting with an ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Eur Heart J 2015 0.81
49 Haematoma after coronary angiography and percutaneous coronary intervention via the femoral artery frequency and risk factors. Eur J Cardiovasc Nurs 2005 0.80
50 Prevention of contrast-induced nephropathy with N-acetylcysteine or sodium bicarbonate in patients with ST-segment-myocardial infarction: a prospective, randomized, open-labeled trial. Circ Cardiovasc Interv 2014 0.79
51 Determinants of the release pattern of ischaemia-modified albumin in acute ST-elevation myocardial infarction treated with primary PCI. Scand J Clin Lab Invest 2010 0.78
52 Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry. EuroIntervention 2010 0.78
53 The risk and prognostic impact of definite stent thrombosis or in-stent restenosis after coronary stent implantation. EuroIntervention 2012 0.78
54 Short and long-term outcome in diabetic patients with acute myocardial infarction in the invasive era. Scand Cardiovasc J 2007 0.77
55 Rationale and design of a randomized clinical comparison of everolimus-eluting (Xience v/Promus) and sirolimus-eluting (cypher select+) coronary stents in unselected patients with coronary heart disease. Cardiology 2010 0.77
56 [Coronary angiography should be considered after out-of-hospital cardiac arrest]. Ugeskr Laeger 2011 0.77
57 Clinical outcome after crush versus culotte stenting of coronary artery bifurcation lesions: the Nordic Stent Technique Study 36-month follow-up results. JACC Cardiovasc Interv 2013 0.76
58 Clinical outcomes after treatment of multiple lesions with zotarolimus-eluting versus sirolimus-eluting coronary stents (a SORT OUT III substudy). BMC Cardiovasc Disord 2012 0.75
59 [Retirement of creatinine kinase myocardial band is not recommended]. Ugeskr Laeger 2008 0.75
60 A third troponin T blood sample is not cost-effective in patients with suspected non-ST segment elevation acute coronary syndrome. Scand J Clin Lab Invest 2010 0.75
61 How well do laboratories follow guidelines on cardiac markers? The cardiac marker guideline uptake in Europe study. Clin Chem 2008 0.75
62 Randomized comparison of deliverability and in-hospital complications in implantation of BxSonic(R), Express(R), and Flexmaster(R) coronary stents. EuroIntervention 2005 0.75
63 Outcomes after revascularisation with everolimus- and sirolimus-eluting stents in patients with acute coronary syndromes and stable angina pectoris: a substudy of the SORT OUT IV trial. EuroIntervention 2014 0.75
64 Extra corporeal life support makes advanced radiologic examinations and cardiac interventions possible in patients with cardiac arrest. Resuscitation 2011 0.75
65 Do laboratories follow heart failure recommendations and guidelines and did we improve? The CARdiac MArker Guideline Uptake in Europe (CARMAGUE). Clin Chem Lab Med 2013 0.75
66 Scintigraphic evaluation of routine filterwire distal protection in percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: a randomized controlled trial. J Nucl Cardiol 2009 0.75
67 Quality assurance of the Western Denmark Heart Registry, a population-based healthcare register. Dan Med J 2017 0.75
68 Biochemical diagnosis of myocardial infarction evolves towards ESC/ACC consensus: experiences from the Nordic countries. Scand Cardiovasc J 2005 0.75